HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dowd, M. T. Articles by Cooper, M. D. Search for Related Content PubMed PubMed Citation Articles by Dowd, M. T. Articles by Cooper, M. D.

Radiation Dose to the Bladder Wall from 2-[¹⁸F] Fluoro-2-deoxy-D-glucose in Adult Humans

The University of Chicago, Department of Radiology, Chicago, Illinois

Correspondence: For reprints contact: Malcolm D. Cooper, MD, University of Chicago, Box 433, FMI, 5841 S. Maryland Ave., Chicago, IL 60637.

ABSTRACT

Accurate determination of the radiation dose to the bladder wall from 2-[¹⁸F]fluoro-2-deoxy-D-glucose (2-[¹⁸F]FDG) is important because the bladder is the critical organ in radiotracer studies using 2-[¹⁸F]FDG. The radiation dose to the bladder wall from injected 2-[¹⁸F]FDG was estimated using both a dynamic bladder model and the conventional MIRD model. The dynamic model takes into account the excretion rate, the varying size of the bladder, the volume at injection, and an estimated bladder time activity curve. Our data from 302 adult subjects in a five-year period indicate that when the bladder is large at the time of injection, the dose to the bladder is greatly reduced. The absorbed dose of the bladder based on the dynamic model for an initial volume of 450 ml is 0.16 ± 0.06 rad/mCi, while that for an initial volume of 200 ml is calculated to be 0.37 ± 0.18 rad/mCi. The MIRD model estimates an average value of 0.35 ± 0.16 rad/mCi for the 302 cases.

This article has been cited by other articles:

				N. M. Scheinin, T. K. Tolvanen, I. A. Wilson, E. M. Arponen, K. A. Nagren, and J. O. Rinne Biodistribution and Radiation Dosimetry of the Amyloid Imaging Agent 11C-PIB in Humans J. Nucl. Med., January 1, 2007; 48(1): 128 - 133. [Abstract] [Full Text] [PDF]

				S. M. Hamblen and V. J. Lowe Clinical 18F-FDG Oncology Patient Preparation Techniques J. Nucl. Med. Technol., March 1, 2003; 31(1): 3 - 10. [Abstract] [Full Text] [PDF]

				T. Tolvanen, K. Lehtio, J. Kulmala, V. Oikonen, O. Eskola, J. Bergman, and H. Minn 18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies J. Nucl. Med., December 1, 2002; 43(12): 1674 - 1680. [Abstract] [Full Text] [PDF]

				T. A. Deterding, J. R. Votaw, C. K. Wang, D. Eshima, L. Eshima, R. Keil, E. Malveaux, C. D. Kilts, M. M. Goodman, and J. M. Hoffman Biodistribution and Radiation Dosimetry of the Dopamine Transporter Ligand [18F]FECNT J. Nucl. Med., February 1, 2001; 42(2): 376 - 381. [Abstract] [Full Text]

				M. C. Graham, H. I. Scher, G.-B. Liu, S. D-J. Yeh, T. Curley, F. Daghighian, S. J. Goldsmith, and S. M. Larson Rhenium-186-labeled Hydroxyethylidene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1307 - 1318. [Abstract] [Full Text] [PDF]